Yatharth Hospital & Trauma Care Services Ltd

Stage 2 · Advancing · week 23Setup 6.2 ★ FairStrong +7.2

As of 16 Oct 2026, Yatharth Hospital & Trauma Care Services is in Stage 2 — advancing, the uptrend phase, in week 23 (since 8 May 2026). It closed at ₹992, 14.6% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.0% of stocks are in Stage 2.

Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. More about the company

₹992.1
+0.06% today
₹9,559 Cr · Mid cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dHospitals & Diagnostic Centres 19.4%-19.4 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

6.2 ★ Fair

Momentum

Steady

Edge

Strong +7.2

Setup-score rank among Stage 2 peers: #1 of 6 in Hospitals & Diagnostic Centres · #10 of 70 in Health Care

Is YATHARTH early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-14.6%
₹550.8 lo₹1,162.2 hi
14.6% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 23
1w13w26w
Week 23 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
23.4%
200 DMA: ₹804.2 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.40x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +0.9% vs MA50 +9.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+1.0%
3M
+17.5%
6M
+28.7%
YTD
+42.6%
1Y
+19.3%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #37 of 66 Stage 2 stocks in Health Care by RS.
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
19.4%
20d Δ
-19.4pp
1M return
-10.4%
3M return
-12.2%
Industry Stage-2 % · last 20 days
Ranks #3 of 5 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-08-07 → 2026-10-16
S? 43w
S2 22w
S2 21w
S2 23w
2023-08-072026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 43w → S3 1w → S2 2w → S3 6w → S2 22w → S3 5w → S4 10w → S1 11w → S2 21w → S3 9w → S4 9w → S1 4w → S2 23w current
Total tracked: 166 weeks across 13 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-16
Pullback Hunter
Latest: 2026-08-21
60 appearances in last 60 days. First seen: 2026-08-04.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 23 · Vol 0.40x
2026-10-15S2
Wk 23 · Vol 0.38x
2026-10-14S2
Wk 23 · Vol 0.77x
2026-10-13S2
Wk 23 · Vol 1.20x
2026-10-12S2
Wk 22 · Vol 0.49x
2026-10-09S2
Wk 22 · Vol 0.47x
2026-10-08S2
Wk 22 · Vol 0.35x
2026-10-07S2
Wk 22 · Vol 0.45x
2026-10-06S2
Wk 22 · Vol 0.64x
2026-10-05S2
Wk 21 · Vol 0.73x
2026-10-01S2
Wk 21 · Vol 0.87x
2026-09-30S2
Wk 21 · Vol 1.53x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹981.5
200 DMA
₹804.2
52W High
₹1,162.2
52W Low
₹550.8
5D Low
₹983.9
Resistance levels (recent highs)
20d High
₹1,162.2
60d High
₹1,162.2
120d High
₹1,162.2
250d High
₹1,162.2
Next resistance
+17.1%
to 20d High
Ask the Market AI about YATHARTHAsk →
P/E (TTM)
44.7
Forward 25.6
Earnings Growth (YoY)
+12.9%
Revenue +47.2%
ROE
+9.9%
Profit margin +14.2%
About this companyHealth Care· Hospitals & Diagnostic Centres

Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.